Revolution Medicines grants equity to CMO Wei Lin

Revolution Medicines Chief Medical Officer Wei Lin reported equity awards that increase his stake in the company.

Rhea-AI Filing Summary

Revolution Medicines Chief Medical Officer Wei Lin reported equity awards that increase his stake in the company. He received a stock option for 34,000 shares at an exercise price of $0.00 per share and a direct grant of 15,100 shares of common stock.

After these awards, Lin directly holds 103,439 shares of common stock, which includes 68,000 restricted stock units. The option vests in equal monthly installments over four years starting on March 1, 2026, contingent on his continued service with the company.

Insider Trade Summary

Grant/Award: 49,100 shares

Grant/Award 2 txns

Insider Wei Lin

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	34,000	$0.00	$0.00
Grant/Award	Common Stock	15,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 34,000 contracts (Direct); Common Stock — 103,439 shares (Direct)

Footnotes (2)

1. F1. Includes 68,000 restricted stock units.
2. F2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Wei Lin report in this RVMD Form 4 filing?

Wei Lin reported new equity awards from Revolution Medicines, including a 34,000-share stock option and 15,100 shares of common stock. These awards increase his direct holdings and form part of his compensation as Chief Medical Officer.

How many Revolution Medicines shares does Wei Lin now own directly?

Wei Lin now directly owns 103,439 shares of Revolution Medicines common stock. This total includes 68,000 restricted stock units that will settle in shares as they vest, reflecting both previously granted awards and the newly reported share grant.

What are the terms of Wei Lin’s new stock option grant at RVMD?

The new stock option covers 34,000 shares at an exercise price of $0.00 per share. One forty-eighth of the shares vests monthly starting March 1, 2026, so the option becomes fully vested after four years of continued service with Revolution Medicines.

When will Wei Lin’s Revolution Medicines stock option fully vest?

The option begins vesting on March 1, 2026, with one forty-eighth of the 34,000 shares vesting each month. All shares will be fully vested and exercisable on the fourth anniversary of that vesting commencement date, assuming Wei Lin continues his service.

What portion of Wei Lin’s RVMD holdings are restricted stock units?

Of Wei Lin’s 103,439 directly held shares of Revolution Medicines common stock, 68,000 are restricted stock units. These units represent a right to receive shares over time, typically subject to vesting conditions tied to his ongoing employment with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 09:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wei Lin

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		15,100	A	$0	103,439(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.02	03/01/2026		A		34,000		(2)	02/28/2036	Common Stock	34,000	$0	34,000	D

Explanation of Responses:

1. Includes 68,000 restricted stock units.

2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Wei Lin	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.